JPRN-UMIN000031763尚未招募未知
Establishment of prevention method for head injury-related venous thromboembolism using anticoagulant. - The new protocol of prophylaxis for head injury-related venous thromboembolism by anticoagulation.
agasaki University Hospital Emergency Medical Center0 个研究点目标入组 50 人开始时间: 2018年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patients that hemostasis is not obtained. The patients with serious liver dysfunction or renal dysfunction. The patients with a history of Heparin-induced thrombocytopenia (HIT). The patients of the drug irritable diathesis such as allergies. The patients who may be pregnant and breast feeding. The patients whom a primary investigator judged to be inadequate for the study.
研究者
相似试验
已完成
不适用
Protecting against brain damage by improving treatment in neonates with hypoglycemia.E16.2Hypoglycaemia, unspecifiedDRKS00024086Heinrich-Heine Universität957
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-BEInstitut de Recherches Internationales Servier18,000
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMEUCTR2005-003700-10-GRInstitut de Recherches Internationales Servier18,000
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-ATInstitut de Recherches Internationales Servier18,000
进行中（未招募）
不适用
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack.The PERFORM Study.An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). - PERFORMIschaemic stroke or transient ischaemic attackMedDRA version: 7.0Level: PTClassification code 10008190EUCTR2005-003700-10-ESaboratorios Servier S.L.18,000